Cassava Sciences (SAVA) Competitors $2.08 -0.01 (-0.48%) As of 11:03 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA vs. CMPS, HUMA, MREO, ERAS, ABVX, BNTC, KMDA, PGEN, ITOS, and RVNCShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include COMPASS Pathways (CMPS), Humacyte (HUMA), Mereo BioPharma Group (MREO), Erasca (ERAS), ABIVAX Société Anonyme (ABVX), Benitec Biopharma (BNTC), Kamada (KMDA), Precigen (PGEN), iTeos Therapeutics (ITOS), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical products" industry. Cassava Sciences vs. Its Competitors COMPASS Pathways Humacyte Mereo BioPharma Group Erasca ABIVAX Société Anonyme Benitec Biopharma Kamada Precigen iTeos Therapeutics Revance Therapeutics COMPASS Pathways (NASDAQ:CMPS) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership. Do insiders and institutionals hold more shares of CMPS or SAVA? 46.2% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 3.9% of COMPASS Pathways shares are owned by insiders. Comparatively, 2.4% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer CMPS or SAVA? COMPASS Pathways presently has a consensus target price of $18.83, suggesting a potential upside of 307.65%. Cassava Sciences has a consensus target price of $54.50, suggesting a potential upside of 2,520.19%. Given Cassava Sciences' higher possible upside, analysts plainly believe Cassava Sciences is more favorable than COMPASS Pathways.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is CMPS or SAVA more profitable? COMPASS Pathways' return on equity of -63.85% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets COMPASS PathwaysN/A -63.85% -51.97% Cassava Sciences N/A -88.05%-64.98% Does the media prefer CMPS or SAVA? In the previous week, COMPASS Pathways and COMPASS Pathways both had 1 articles in the media. COMPASS Pathways' average media sentiment score of 1.87 beat Cassava Sciences' score of 1.61 indicating that COMPASS Pathways is being referred to more favorably in the media. Company Overall Sentiment COMPASS Pathways Very Positive Cassava Sciences Very Positive Which has stronger valuation & earnings, CMPS or SAVA? COMPASS Pathways is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOMPASS PathwaysN/AN/A-$118.46M-$1.99-2.32Cassava SciencesN/AN/A-$97.22M-$1.50-1.39 Does the MarketBeat Community believe in CMPS or SAVA? Cassava Sciences received 29 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 82.14% of users gave COMPASS Pathways an outperform vote while only 64.47% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformCOMPASS PathwaysOutperform Votes6982.14% Underperform Votes1517.86%Cassava SciencesOutperform Votes9864.47% Underperform Votes5435.53% Which has more volatility & risk, CMPS or SAVA? COMPASS Pathways has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -1.99, meaning that its share price is 299% less volatile than the S&P 500. SummaryCOMPASS Pathways beats Cassava Sciences on 9 of the 14 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.48M$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-1.518.8527.2320.02Price / SalesN/A256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book0.646.617.124.70Net Income-$97.22M$143.93M$3.23B$247.97M7 Day Performance-1.89%3.84%2.74%2.64%1 Month Performance13.66%11.14%8.94%6.39%1 Year Performance-89.09%4.35%31.59%13.95% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences4.2849 of 5 stars$2.08-0.5%$54.50+2,520.2%-88.9%$100.48MN/A-1.5130Positive NewsCMPSCOMPASS Pathways2.6317 of 5 stars$4.37+5.0%$18.83+331.0%-28.2%$408.87MN/A-1.99120Positive NewsGap UpHUMAHumacyte2.5208 of 5 stars$2.62-1.9%$11.71+347.1%-63.7%$406.41M$517K-1.96150Positive NewsAnalyst ForecastAnalyst RevisionMREOMereo BioPharma Group1.9341 of 5 stars$2.55+18.6%$7.71+202.5%-24.7%$405.45M$1M-36.4340Positive NewsAnalyst RevisionERASErasca2.7709 of 5 stars$1.43+1.8%$4.57+220.8%-32.4%$403.68MN/A-1.72120Positive NewsABVXABIVAX Société Anonyme2.001 of 5 stars$6.35+5.5%$31.00+388.2%-47.3%$402.82MN/A0.0061Analyst RevisionGap UpBNTCBenitec Biopharma2.263 of 5 stars$15.61+1.6%$24.71+58.3%+120.8%$399.62M$80K-10.3420KMDAKamada3.8304 of 5 stars$6.90+0.7%$14.67+112.6%+36.3%$396.61M$167.24M24.64360Positive NewsShort Interest ↑PGENPrecigen4.1585 of 5 stars$1.33+0.8%$7.00+426.3%-8.5%$392.59M$4.20M-2.42190Analyst RevisionITOSiTeos Therapeutics3.8712 of 5 stars$10.02flat$15.86+58.3%-38.7%$383.51M$35M-3.1890Insider TradeHigh Trading VolumeRVNCRevance Therapeutics2.5937 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500 Related Companies and Tools Related Companies COMPASS Pathways Competitors Humacyte Competitors Mereo BioPharma Group Competitors Erasca Competitors ABIVAX Société Anonyme Competitors Benitec Biopharma Competitors Kamada Competitors Precigen Competitors iTeos Therapeutics Competitors Revance Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAVA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SAVA Stock Free SAVA Stock Alerts